Wednesday, November 10, 2010

Amgen Scholars Undergraduate Summer Research Program Begins Phase 2

Eight-Year, $34 Million Program, in Partnership with 13 Top Universities, Will Reach Nearly 2,500 Undergraduates

THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire via COMTEX/—Today, Amgen Scholars, the signature initiative of the Amgen Foundation, moves into its second phase of what has become a $34 million program to advance science learning and inspire the next generation of scientists.

Read the rest of this entry

Posted in Press Releases

Tuesday, November 09, 2010

Amgen to Present at 19th Annual Credit Suisse Healthcare Conference

THOUSAND OAKS, Calif., Nov. 9, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) will participate in the 19th Annual Credit Suisse Healthcare Conference on Friday, Nov. 12, 2010, at the Biltmore Hotel in Phoenix, Ariz., beginning at 8:30 a.m. Mountain Time. Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s website, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Monday, November 08, 2010

Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer

Bone is One of the Most Common Sites for Distant Metastases Affecting up to 75 percent of Patients with Advanced Breast Cance

THOUSAND OAKS, Calif., Nov. 8, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa® (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases. An SRE consists of any of the following: a pathologic fracture, the need for radiation or surgery to ameliorate bone pathology secondary to tumor growth, or spinal cord compression. The study, published today in the Journal of Clinical Oncology, found that denosumab was superior to Zometa in delaying or preventing SREs in breast cancer patients with bone metastases.

Read the rest of this entry

Posted in Press Releases

Saturday, November 06, 2010

Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership

Collaboration Aims to Empower Patients with Psoriatic Arthritis and Rheumatoid Arthritis to Seek Care

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., Nov. 6, 2010 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN), Pfizer Inc. (NYSE: PFE) and world-class professional golfer Phil Mickelson, have entered into a partnership to share Phil’s experience with his diagnosis of psoriatic arthritis and treatment with Enbrel® (etanercept), and to encourage patients with similar symptoms to visit their doctor for proper assessment and care.

Read the rest of this entry

Posted in Press Releases

Friday, November 05, 2010

Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards

THOUSAND OAKS, Calif., Nov. 5, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) is pleased to announce that it has won the Best New Drug awardfor Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME’s Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone.

Read the rest of this entry

Posted in Press Releases